{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/eczema-atopic/","result":{"data":{"firstChapter":{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field e266eacf-ffc8-47db-8e20-e542079a3393 --><h1>Eczema - atopic: Summary</h1><!-- end field e266eacf-ffc8-47db-8e20-e542079a3393 -->","htmlStringContent":"<!-- begin item 35209149-9917-475a-80b5-1e14fcdd4346 --><!-- begin field d87ef562-0d7a-423d-b36e-f36e88fcaa7b --><ul><li>Atopic eczema is a chronic, itchy, inflammatory skin condition that affects people of all ages, although it presents most frequently in childhood. Around 70–90% of cases occur before 5 years of age, with a high incidence of onset in the first year of life.</li><li>It is typically an episodic disease of flares (exacerbations, which may occur as frequently as two or three times each month) and remissions; in severe cases, disease activity may be continuous. </li><li>Atopic eczema is a complex condition. Genetic predisposition, skin barrier dysfunction, environmental factors (such as exposure to pets, house-dust mites, and pollen), and immune system dysfunction are thought to play a role in its development.</li><li>Complications include:<ul><li>Infection, such as bacterial infection with <em>Staphylococcus aureus</em>, herpes simplex virus infection (may be widespread if eczema herpeticum), or superficial fungal infection.</li><li>Psychosocial issues, such as missing school, depression, disturbed sleep, and reduced self-confidence.</li></ul></li><li>The diagnosis of atopic eczema is primarily clinical. Investigations are not routinely required but may be useful in excluding differential diagnoses.</li><li>At each consultation, the severity of the eczema and the psychological impact should be assessed.</li><li>A stepped approach is recommended for the management of atopic eczema:<ul><li>Emollients are the first-line treatments during both acute flares and remissions of the condition.</li><li>The use of topical steroids should be considered for red, inflamed skin. The lowest potency and amount of topical corticosteroid necessary to control symptoms should be prescribed, depending on the severity of the flare. </li><li>If there is persistent, severe itch, or urticaria, a one-month trial of a non-sedating antihistamine should be considered.</li><li>If itching is severe and affecting sleep, a short course of a sedating antihistamine should be considered (if appropriate).</li><li>If there is severe, extensive eczema, a short course of oral corticosteroids should be considered.</li><li>If eczema is weeping, crusted, or there are pustules, with fever or malaise, secondary bacterial infection should be considered, and antibiotic treatment should be prescribed. </li></ul></li><li>Providing appropriate information on the nature of eczema and advice on the importance of adherence to skin care measures and avoidance of trigger factors (where possible) are essential for disease maintenence and management of flares.</li><li>Immediate hospital admission should be arranged if eczema herpeticum (characterized by rapidly worsening, painful eczema; clustered blisters; and punched out erosions) is suspected.</li><li>Referral to a dermatologist should be considered if:<ul><li>The diagnosis is uncertain.</li><li>Eczema is not controlled with current treatment.</li><li>There is recurrent secondary infection.</li><li>Treatment advice is needed (such as bandaging techniques).</li></ul></li><li>Referral to an immunologist, paediatrician, or dermatologist should be considered if a food allergy trigger is suspected and the expertise to diagnose and manage food allergy is not available in primary care.</li><li>Referral to a clinical psychologist should be arranged for people whose eczema is controlled but whose quality of life and psychological well-being have not improved (this may not be directly related to the severity of the eczema).</li></ul><!-- end field d87ef562-0d7a-423d-b36e-f36e88fcaa7b --><!-- end item 35209149-9917-475a-80b5-1e14fcdd4346 -->","topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","aliases":[],"chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","slug":"management","fullItemName":"Management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","aliases":[],"topicSummary":"Atopic eczema is a chronic, itchy, inflammatory skin condition that affects people of all ages, although it presents most frequently in childhood.","lastRevised":"Last revised in January 2021","nextPlannedReviewBy":"2022-01-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2022-01","nextPlannedReviewByDisplay":"January 2022","specialities":[{"id":"50071c38-ab10-5ab8-ac70-6bd19a96c24e","name":"Skin and nail","slug":"skin-nail"}],"chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","slug":"management","fullItemName":"Management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c"}},"staticQueryHashes":["3666801979"]}